Junwei Huo1, Jing Hu2, Gaowei Liu1, Yajie Cui3, Ying Ju4. 1. Department of Gynaecology and Obstetrics, The First Hospital of Yulin, Yulin, Shaanxi, 718000, China. 2. Department of Gynaecology and Obstetrics, Xi'an Central Hospital, Xi'an, Shaanxi, 710003, China. 3. Department of Gynaecology and Obstetrics, Xi'an No 1. Hospital, Xi'an, Shaanxi, 710003, China. 4. Department of Gynaecology and Obstetrics, Tangdu Hospital, The Fourth Military Medical University, No 1, Xinsi Road, Baqiao District, Xi'an, Shaanxi, 710038, China. eager_ju@sina.com.
Abstract
PURPOSE: Interleukin-37 (IL-37) has been identified as a novel anti-inflammatory cytokine which is involved in tumor development. This study aimed to evaluate the expression of IL-37 in serum and determine its clinical significance in human epithelial ovarian cancer (EOC). METHODS: Enzyme-linked immunosorbent assay (ELISA) was performed to examine the serum IL-37 levels in 76 patients with EOC and 76 healthy controls. The association of IL-37 levels with clinical factors and prognosis of EOC patients was analyzed. The diagnostic accuracy of serum IL-37 was performed by receiver operator characteristic (ROC) curve analysis. RESULTS: Serum IL-37 levels in patients with EOC (187.3 ± 75.57 pg/ml) were significantly higher than those in healthy controls (84.89 ± 28.92 pg/ml, P < 0.001). High serum IL-37 levels were significantly associated with FIGO stage (P < 0.001), tumor size (P = 0.002), lymph node metastasis (P = 0.021), positive recurrence (P = 0.047) and residual tumor size (P < 0.001). The Kaplan-Meier survival analysis demonstrated that high serum IL-37 levels were significantly associated with poor overall survival and the progression-free survival (log-rank, P = 0.026, and P = 0.039, respectively). Univariate and multivariate analysis indicated that serum IL-37 levels (HR = 3.007, 95% CI 2.125-4.842, P = 0.008) were an independent prognostic factor for EOC patients. ROC curve analyses revealed an AUC (the areas under the ROC curve) of 0.881 (95% CI 0.829-0.945; P < 0.001). CONCLUSIONS: High serum IL-37 levels are associated with an unfavorable prognosis of EOC patients. IL-37 may serve as a promising and useful prognostic biomarker for EOC.
PURPOSE:Interleukin-37 (IL-37) has been identified as a novel anti-inflammatory cytokine which is involved in tumor development. This study aimed to evaluate the expression of IL-37 in serum and determine its clinical significance in humanepithelial ovarian cancer (EOC). METHODS: Enzyme-linked immunosorbent assay (ELISA) was performed to examine the serum IL-37 levels in 76 patients with EOC and 76 healthy controls. The association of IL-37 levels with clinical factors and prognosis of EOC patients was analyzed. The diagnostic accuracy of serum IL-37 was performed by receiver operator characteristic (ROC) curve analysis. RESULTS: Serum IL-37 levels in patients with EOC (187.3 ± 75.57 pg/ml) were significantly higher than those in healthy controls (84.89 ± 28.92 pg/ml, P < 0.001). High serum IL-37 levels were significantly associated with FIGO stage (P < 0.001), tumor size (P = 0.002), lymph node metastasis (P = 0.021), positive recurrence (P = 0.047) and residual tumor size (P < 0.001). The Kaplan-Meier survival analysis demonstrated that high serum IL-37 levels were significantly associated with poor overall survival and the progression-free survival (log-rank, P = 0.026, and P = 0.039, respectively). Univariate and multivariate analysis indicated that serum IL-37 levels (HR = 3.007, 95% CI 2.125-4.842, P = 0.008) were an independent prognostic factor for EOC patients. ROC curve analyses revealed an AUC (the areas under the ROC curve) of 0.881 (95% CI 0.829-0.945; P < 0.001). CONCLUSIONS: High serum IL-37 levels are associated with an unfavorable prognosis of EOC patients. IL-37 may serve as a promising and useful prognostic biomarker for EOC.
Authors: Katrin Hefler-Frischmuth; Christoph Grimm; Lisa Gensthaler; Elisabeth Reiser; Richard Schwameis; Lukas A Hefler Journal: Wien Klin Wochenschr Date: 2018-09-03 Impact factor: 1.704
Authors: Douglas G Osborne; Joanne Domenico; Yuchun Luo; Anna L Reid; Carol Amato; Zili Zhai; Dexiang Gao; Melanie Ziman; Charles A Dinarello; William A Robinson; Mayumi Fujita Journal: Mol Carcinog Date: 2019-05-16 Impact factor: 5.139
Authors: Danielle M Santarelli; Fabien B Vincent; Ina Rudloff; Claudia A Nold-Petry; Marcel F Nold; Marc A Russo Journal: Front Immunol Date: 2021-07-23 Impact factor: 7.561